Columbia University Medical Center (CUMC) is a pioneer in investigating treatment solutions for valve disease and has conducted more original research in the area of valve therapy than any other institution in the United States. We served as the lead investigational site for the pivotal PARTNER Trial (Placement of AoRTic TraNscathetER Valve), which led to the approval of transcatheter aortic valve replacement (TAVR) in the United States in 2011. As a result of our involvement, CUMC has now performed over 900 research and FDA-approved TAVRs, more than any other center in the United States. Today, we are involved in the PARTNER II Trial which is evaluating TAVR for an expanded patient population. Additionally, we are participating in the COAPT Trial which is examining the safety and effectiveness of a minimally invasive catheter-based treatment for mitral valve disease. We also are actively involved in many research studies evaluating minimally invasive surgical therapies.
CUMC is also is a leader in academic throughput and in 2012 published eight papers alone on the PARTNER Trial in some of the most prestigious medical journals in the world including two in the New England Journal of Medicine:
- Two-year outcomes after transcatheter or surgical aortic-valve replacement
- TAVR for inoperable severe AS.
In fact, CUMC serves as the PARTNER Publications Office in collaboration with our partners, establishing a new model for clinical trial publications. Additionally, under the leadership of Martin B. Leon, MD, CUMC founded the Valve Academic Research Consortium (VARC) which helped to standardized endpoint definitions for TAVR.
Finally, our Center serves as one of just a few training sites in the United States on TAVR. In fact, CUMC has trained close to 50 percent of the heart teams in the U.S. who now perform TAVR in their own centers.